Syntis Bio
MILTON, MA · Biotechnology · 25 employees
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestin
Funding history
- Funding Round — $25.0M — Jul 2025
- Series series a — $33.0M — Jul 2025
- Funding Round — $6.3M — Jan 2025
- Funding Round — $15.4M — Jan 2023
- Funding Round — $15.4M — Aug 2022
Recent signals
- Jun 09, 2026: Syntis Bio Appoints Matthew Dallas as Chief Financial Officer
- Mar 03, 2026: Syntis Bio Appoints David Rosenbaum as Chief Development Officer and Christo Shalish as Chief Business Officer
- Jul 02, 2025: Raised $25.0M
- Jul 01, 2025: Raised $33.0M in Series series a
- Jan 27, 2025: Raised $6.3M
- Jan 17, 2023: Raised $15.4M
- Aug 17, 2022: Raised $15.4M
See plans & pricing → Track Syntis Bio’s funding, hiring, and signals — with verified contacts — on Fundz.